Skip to main content
Clinical Trials/NCT02515266
NCT02515266
Completed
Not Applicable

Evaluation of Additional Protein Fortification in Extremely Low Birth Weight Infants Fed Human Milk: PROTSUP Study

Hôpital de la Croix-Rousse0 sites152 target enrollmentMay 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Premature Birth
Sponsor
Hôpital de la Croix-Rousse
Enrollment
152
Primary Endpoint
Change from baseline body weight z-scores to 1 and 2 weeks after additional protein fortification
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Postnatal growth is a crucial in premature infants as it could be correlated with the long-term cognitive development. Optimal nutritional care is required to reduce the initial weight loss and further growth deficit.

The quantitative objective is to achieve growth that is at least equivalent to that of the fetus (on average 15 g/kg.day (12-18 g/kg.day according to gestational age). Children often grow during difficult 10-15 first days of life, so they accumulate a delay that should compensate them secondarily. Therefore, optimum postnatal growth is rather 20 g/kg.day than 15 g/kg.day.

Individualized fortification of human milk (HM) has been proposed to optimize postnatal growth. Specifically, the lack of protein intake is responsible for sub-optimal postnatal growth in preterm infants.

The objectives of this study are to determine the effectiveness of additional protein fortification (APF) in terms of short-term growth along with the proportion of extremely low birth weight (ELBW) infants requiring APF.

Detailed Description

In a retrospective, single-center study, premature infants weighing \<1250 g at birth hospitalized in investigators' neonatal intensive care unit in 2012, who were exclusively fed with fortified HM and received APF for \>12 consecutive days were included. Weight gain (g/kg•d) over the previous 7 days was calculated daily based on weight data in patients' electronic medical records. When weight gain was considered insufficient (i.e., below 20 g/kg•d) and the serum urea level was \<3 mmol/L, 1 g/kg•d protein was added. Before using the mixture, investigators verified that the osmolality was only slightly increased (from 412 to 422 mOsm/kg). Growth and digestive tolerance were compared between the week before (Wk0) and 1 and 2 weeks after (Wk1 and Wk2, respectively) the introduction of protein supplement; each participant served as his own control. Change from baseline for body weight was the main outcome. Energy and protein intake during Wk0, Wk1, and Wk2 were calculated. Standard deviation z-scores for growth parameters were calculated 7 days before, at time of protein introduction, and 7 and 14 days after . Changes in Z-scores were calculated. The digestive tolerance score and metabolic tolerance (serum urea) were assessed during Wk0, Wk1, and Wk2 (5).

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
July 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hôpital de la Croix-Rousse
Responsible Party
Principal Investigator
Principal Investigator

Jean-charles PICAUD, MD, PhD

Head of department of neonatology

Hôpital de la Croix-Rousse

Eligibility Criteria

Inclusion Criteria

  • infants weighing \<1250 g at birth
  • exclusively fed with fortified HM

Exclusion Criteria

  • Severe malformations

Outcomes

Primary Outcomes

Change from baseline body weight z-scores to 1 and 2 weeks after additional protein fortification

Time Frame: One and two weeks after the beginning of additional protein fortification

Similar Trials